Eurofins Scientific Shares Drop 11% in a Week Following Disappointing Results
Eurofins Scientific drops 1.66% this Thursday afternoon, trading at €61.60, following the release of mixed quarterly results the day before. The stock has continued its downward trajectory over the past week, declining more than 11% over seven days, even as the CAC 40 index rises by 0.74% during the session.
Underperformance Triggered by Quarterly Financials
The decline in Eurofins Scientific's stock can be attributed to the release on Wednesday of its first quarter 2026 figures. The company, specializing in bioanalytical services, reported organic growth limited to 2.5%, hindered by challenging weather conditions in Northern Europe and North America, as well as the deliberate termination of unprofitable contracts. This growth rate, below expectations, has weighed on the stock since its announcement. However, the management highlighted notable improvements in profitability and margins, while reaffirming their annual targets. This message failed to reassure, as the market seems to place more emphasis on revenue dynamics than on profitability gains. The general meeting, taking place this Thursday, April 23, could provide an opportunity for the management to clarify their strategic directions for the remainder of the fiscal year. The next semi-annual results are expected on September 18.
Technical Analysis Indicates Deteriorating Mid-Term Trend
From a technical standpoint, the current price of €61.60 is now significantly below all its moving averages, including the MM50 (€65.04) and the MM200 (€63.84). This positioning reflects a deterioration of the mid-term trend. The stock is also trading in the lower part of its Bollinger Bands, at only 19% of the range between the lower bound (€59.29) and the upper bound (€71.36), an area often associated with potential oversold conditions. The RSI, at 41, confirms weakened momentum but does not yet indicate a marked overselling. The nearest support threshold is at €60.76, a level not yet tested this Thursday. A downward breach of this threshold could intensify selling pressure. Despite a decline of more than 13% over three months, the stock still maintains a positive performance of nearly 25% over the year, which puts the recent correction into a longer-term perspective.
